Egetis Therapeutics AB
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Egetis Therapeutics AB
The Swedish firm has decided to pass on a bid from a proposed buyer which would have involved a healthy premium but “considerably undervalued” its long-term prospects.
With an EU submission imminent for its MCT8 deficiency therapy Emcitate, Egetis is in talks with “certain external partners” about an acquisition.
Compassionate use programs (CUP) are a developing field in Asian countries. In the majority of Asian states, the CU applies to Named-Patients Program (NPP). In the most countries, understanding of CUP for unapproved drugs is poor among the public, and even for professional communities.
Biopharma industry leaders highlight key concerns and opportunities across production, supply chain and commercial operations. Business transformation is top of mind for many, perhaps unsurprisingly following two years of rapid and mostly successful adaptation to the strictures of the COVID-19 pandemic.
- Other Names / Subsidiaries
- Rare Thyroid Therapeutics International AB
- PledPharma AB
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.